Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu

This publication has 16 references indexed in Scilit:

• Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
  Journal of Clinical Oncology, 1999
• Clinical and Immune Responses in Resected Colon Cancer Patients Treated With Anti-Idiotype Monoclonal Antibody Vaccine That Mimics the Carcinoembryonic Antigen
  Journal of Clinical Oncology, 1999
• In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.
  British Journal of Cancer, 1998
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
  Journal of Clinical Oncology, 1998
• Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
  Nature, 1998
• Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ‘self’ tumour antigens
  Immunology, 1998
• HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
  Published by Elsevier ,1997
• Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies
  European Journal Of Cancer, 1996
• c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis
  British Journal of Cancer, 1992
• Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.
  Journal of Clinical Investigation, 1990